Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, 9500 Gilman Drive, Mail Code 0507, La Jolla, CA, 92093-0507, USA.
Universidad Xochicalco, Facultad de Medicina, Campus Tijuana, Rampa Yumalinda 4850, Chapultepec Alamar, 22110, Tijuana, B.C., Mexico.
BMC Public Health. 2022 Apr 27;22(1):842. doi: 10.1186/s12889-022-13273-y.
People who inject drugs (PWID) are vulnerable to SARS-CoV-2 infection. We examined correlates of COVID-19 testing among PWID in the U.S.-Mexico border region and described encounters with services representing potential opportunities (i.e., 'touchpoints') where COVID-19 testing could have been offered.
Between October, 2020 and September, 2021, participants aged ≥18 years from San Diego, California, USA and Tijuana, Baja California, Mexico who injected drugs within the last month completed surveys and SARS-CoV-2, HIV, and HCV serologic testing. Logistic regression identified factors associated with COVID-19 testing including potential touchpoints, comorbidities and COVID-19 related misinformation and disinformation.
Of 583 PWID, 30.5% previously had a COVID-19 test. Of 172 PWID who tested SARS-CoV-2 seropositive (30.1%), 50.3% encountered at least one touchpoint where COVID-19 testing could have been offered within the prior six months. Factors independently associated with at least two fold higher odds of COVID-19 testing were living in San Diego, recent incarceration, receiving substance use treatment, and experiencing ≥1 chronic health condition. Homelessness, having received ≥1 dose of COVID-19 vaccine, and having a HIV or HCV test since the COVID-19 epidemic began were also independently associated with having had a prior COVID-19 test.
We identified several factors independently associated with COVID-19 testing and multiple touchpoints where COVID-19 testing could be scaled up for PWID, such as SUD treatment programs and syringe service programs. Integrated health services are needed to improve access to rapid, free COVID-19 testing in this vulnerable population.
注射毒品者(PWID)易感染 SARS-CoV-2。我们研究了美国-墨西哥边境地区 PWID 进行 COVID-19 检测的相关因素,并描述了在可能提供 COVID-19 检测的服务接触点(即“接触点”)中遇到的情况。
在 2020 年 10 月至 2021 年 9 月期间,来自美国加利福尼亚州圣地亚哥和墨西哥下加利福尼亚州提华纳的年龄≥18 岁、过去一个月内注射过毒品的参与者完成了调查和 SARS-CoV-2、HIV 和 HCV 血清学检测。Logistic 回归分析确定了与 COVID-19 检测相关的因素,包括潜在的接触点、合并症以及与 COVID-19 相关的错误信息和虚假信息。
在 583 名 PWID 中,30.5%的人之前接受过 COVID-19 检测。在 172 名 SARS-CoV-2 血清学检测呈阳性的 PWID 中(30.1%),50.3%的人在过去六个月内至少遇到过一个可以提供 COVID-19 检测的接触点。与 COVID-19 检测的可能性增加至少两倍相关的独立因素包括居住在圣地亚哥、最近被监禁、接受药物使用治疗以及经历≥1 种慢性健康状况。无家可归、接受过≥1 剂 COVID-19 疫苗接种以及自 COVID-19 大流行开始以来接受过 HIV 或 HCV 检测,也与之前接受过 COVID-19 检测独立相关。
我们确定了几个与 COVID-19 检测相关的独立因素,以及多个可以为 PWID 扩大 COVID-19 检测的接触点,例如药物滥用治疗计划和注射器服务计划。需要提供综合健康服务,以改善弱势群体对快速、免费 COVID-19 检测的获取。